Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Planchard, Benjamin Besse, Tae Min Kim, Elisabeth A. Quoix, Pierre Jean Souquet, Julien Mazieres, Fabrice Barlesi, Harry J.M. Groen, Egbert F. Smit, Christina S. Baik, Byoung Chul Cho, Ronan Joseph Kelly, Mark A. Socinski, Silvia Novello, James R. Rigas, Vanessa Giannone, Anthony Michael D'amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson
Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, Seoul National University Hospital, Hôpitaux Universitaires de Strasbourg, Hôpital Lyon Sud, Université Toulouse III - Paul Sabatier, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, University Medical Center Groningen, University of Groningen, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Washington, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Pittsburgh, University of Turin, Dartmouth College, Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2753459921